arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 7/2017 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Profiteering with orphan drugs … 450-fold price increase within seven years

    NEW ON THE MARKET

    Baricitinib (OLUMIANT) and tofacitinib (XELJANZ) against rheumatoid arthritis

    THERAPY FROM A CRITICAL VIEWPOINT

    CANVAS trial with canagliflozin (INVOCANA) – second endpoint trial with an SGLT-2 inhibitor

    Bioresorbable coronary stents: disappointing results

    a-t READERS QUESTIONS AND COMMENTS

    Glatiramer acetate generic CLIFT

    IN BRIEF

    SCORE 2 trial: bevacizumab (AVASTIN) versus aflibercept (EYLEA) in retinal vein occlusion

    No benefit of high dose baclofen (LIORESAL, generics) in alcohol-dependent patients

    Azithromycin gel against borreliosis?

    CURRENT ADR NETWORK REPORT

    Genital mycosis with empagliflozin (JARDIANCE)

    SIDE EFFECTS

    Fatal liver failure with daclizumab (ZINBRYTA)
    free

    Cardiovascular side effects with brimonidine (MIRVASO)

    e a-t ON THE INTERNET

    Osteonecrosis of the external auditory canal with denosumab (PROLIA, XGEVA)

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles